CVS/CVS

$69.50

1.25%
-
1D1W1MYTD1YMAX

About CVS

CVS Health Corporation is a health solutions company. The Company operates in four segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, and Corporate/Other. Its Health Care Benefits segment offer a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare supplement plans, and Medicaid health care management services. Its Health Services segment provides a full range of pharmacy benefit management solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations, provides ancillary pharmacy services, including pharmacy patient care programs, diagnostic testing and vaccination administration.

Ticker

CVS

Sector

Healthcare

Trading on

NYSE

Industry

Retail (Drugs)

CEO

Karen Lynch

Employees

300,000

Headquarters

Woonsocket, United States

CVS Metrics

BasicAdvanced
$86.52B
Market cap
10.61
P/E ratio
$6.47
EPS
0.54
Beta
$2.64
Dividend rate
3.88%
Dividend yield
$86.52B
0.5386
$83.25
$64.41
10.11M
$2.64
0.857
0.629
76.69
80.577
37.61%
20.826
5.69%
3.5%
11.28%
5.09%
10.614
0.242
1.156
11.912
2.59%
3.84%
3.88%
10.95%
99.37%
10.01%
5.74%
9.65%

What the Analysts think about CVS

Analyst Ratings

Majority rating from 29 analysts.
Buy

Price Targets

Average projection from 24 analysts.
25.32% upside
High $99.00
Low $74.00
$69.50
Current price
$87.10
Average price target

CVS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
2.18% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$93.81B
4.51%
Net income
$2.05B
-9.51%
Profit margin
2.18%
-13.15%

CVS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.5%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$2.20
$2.21
$2.21
$2.12
-
Expected
$2.09
$2.11
$2.13
$1.99
$1.71
Surprise
5.32%
4.85%
3.54%
6.5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for CVS stock?

CVS (CVS) has a market cap of $86.52B as of April 15, 2024.

What is the P/E ratio for CVS stock?

The price to earnings (P/E) ratio for CVS (CVS) stock is 10.61 as of April 15, 2024.

Does CVS stock pay dividends?

Yes, the CVS (CVS) stock pays dividends to shareholders. As of April 15, 2024, the dividend rate is $2.63675 and the yield is 3.88%. CVS has a payout ratio of 37.61% on a trailing twelve-month basis.

When is the next CVS dividend payment date?

The next CVS (CVS) dividend payment is scheduled for May 01, 2024.

What is the beta indicator for CVS?

CVS (CVS) has a beta rating of 0.54. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the CVS stock price target?

The target price for CVS (CVS) stock is $87.1, which is 25.32% above the current price of $69.5. This is an average based on projections from 24 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell CVS stock

Buy or sell CVS stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing